← Back to Clinical Trials
Recruiting NCT06725186

NCT06725186 Regulating Emotions Like An eXpert Among Adolescents With ADHD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06725186
Status Recruiting
Phase
Sponsor Virginia Polytechnic Institute and State University
Condition RELAX Telehealth Intervention
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-01-15
Primary Completion 2027-05

Eligibility & Interventions

Sex All sexes
Min Age 11 Years
Max Age 16 Years
Study Type INTERVENTIONAL
Interventions
RELAXPsychoeducational Materials

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-01-15 with a primary completion date of 2027-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study consists of a randomized controlled trial assessing the acceptability, feasibility, and efficacy of the RELAX (Regulating Emotions Like An eXpert) Intervention. Following randomization, 30 families will receive the RELAX intervention and 30 families will receive psychoeducational materials as part of a control condition. Additionally, 10 families from the RELAX condition will participate in a pilot study and focus groups to give feedback on developed smartphone apps to support skill use during and following completion of RELAX.

Eligibility Criteria

Inclusion Criteria: * child with ADHD in middle or high school at time of study entry * child has an estimated verbal IQ \>=80 based on the Wechsler Intelligence Scale for Children, Fifth Edition Verbal Comprehension Index * child has no evidence of severe developmental delay either from genetic origins (e.g., Down Syndrome) or complications during pregnancy/birth (e.g., infection, micropremature) * participating parent/legal guardian has custody/medical decision making of the child * family uses English as one of their primary languages (i.e., able to participate in study visits and intervention conducted in English) Exclusion Criteria: * child not diagnosed with ADHD as confirmed by prior documented diagnosis and/or current comprehensive ADHD assessment as part of intake visit * having a child outside of the eligible age range of 11-16 at time of study enrollment * participating parent not having legal custody of the child * having parents or children who are not fluent in English * having a child with a severe developmental delay either from genetic origins (e.g., Down Syndrome) or complications from pregnancy/birth (e.g., infection, micro-premature) * child has an IQ \< 70.

Contact & Investigator

Central Contact

Rosanna Breaux, PhD

✉ calmerlab@gmail.com

📞 5402318276

Principal Investigator

Rosanna Breaux, PhD

PRINCIPAL INVESTIGATOR

Virginia Polytechnic Institute and State University

Frequently Asked Questions

Who can join the NCT06725186 clinical trial?

This trial is open to participants of all sexes, aged 11 Years or older, up to 16 Years, studying RELAX Telehealth Intervention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06725186 currently recruiting?

Yes, NCT06725186 is actively recruiting participants. Contact the research team at calmerlab@gmail.com for enrollment information.

Where is the NCT06725186 trial being conducted?

This trial is being conducted at Blacksburg, United States.

Who is sponsoring the NCT06725186 clinical trial?

NCT06725186 is sponsored by Virginia Polytechnic Institute and State University. The principal investigator is Rosanna Breaux, PhD at Virginia Polytechnic Institute and State University. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology